Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease

被引：15

作者：

Zhang, Jing ^{[1
]}

Romero, Jan ^{[1
]}

Chan, Audrey ^{[1
]}

Goss, Jennifer ^{[1
]}

Stucka, Sabrina ^{[1
]}

Cross, Jason ^{[1
]}

Chamberlain, Brian ^{[1
]}

Varoglu, Mustafa ^{[1
]}

Chandonnet, Haoqun ^{[1
]}

Ryan, Dominic ^{[1
]}

Lippa, Blaise ^{[1
]}

机构：

[1] Cubist Pharmaceut, Lexington, MA 02421 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 17期

关键词：

IBD; Crohn's disease; Ulcerative colitis; CCR9; Sulfonamide; CELLS; LOCALIZATION; LYMPHOCYTES; RECEPTOR;

D O I：

10.1016/j.bmcl.2015.06.046

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：3661 / 3664

页数：4

共 50 条

[1] CCR9 and inflammatory bowel disease
Koenecke, Christian
Foerster, Reinhold
EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (03) : 297 - 306
[2] CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease
Wendt, Emily
Keshav, Satish
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2015, 8 : 119 - 130
[3] Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease
Bekker, P.
Keshav, S.
Wei, Z.
Ertl, L.
Wang, Y.
Lai, N.
Wright, J.
Ungashe, S.
Schall, Thomas
INFLAMMATION RESEARCH, 2007, 56 : S350 - S350
[4] Chemokine receptor 9 (CCR9) polymorphisms: Susceptibility genes for inflammatory small bowel disease?
McGovern, DP
Van Heel, D
Dechairo, B
Ahmad, T
Lench, N
Anderson, R
Jewell, D
GASTROENTEROLOGY, 2002, 122 (04) : A302 - A302
[5] A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease
Kalindjian, S. Barret
Kadnur, Sanjay V.
Hewson, Christopher A.
Venkateshappa, Chandregowda
Juluri, Suresh
Kristam, Rajendra
Kulkarni, Bheemashankar
Mohammed, Zainuddin
Saxena, Rohit
Viswanadhan, Vellarkad N.
Aiyar, Jayashree
McVey, Donna
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (07) : 3098 - 3111
[6] Discovery of indole inhibitors of chemokine receptor 9 (CCR9)
Pandya, Bhaumik A.
Baber, Christian
Chan, Audrey
Chamberlain, Brian
Chandonnet, Haoqun
Goss, Jennifer
Hopper, Timothy
Lippa, Blaise
Poutsiaka, Katherine
Romero, Jan
Stucka, Sabrina
Varoglu, Mustafa
Zhang, Jing
Zhang, Xin
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (14) : 3322 - 3325
[7] Pharmacological inhibition of gut homing CCR9 T-cells alters disease severity in murine models of inflammatory bowel disease
Wei, Z.
Walters, M.
Ertl, L.
Wang, Y.
Ungashe, S.
Schall, T.
INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 644 - 644
[8] CCR9 homes metastatic melanoma cells to the small bowel
Richmond, Ann
CLINICAL CANCER RESEARCH, 2008, 14 (03) : 621 - 623
[9] Letter: the therapeutic potential of targeting CCL25/CCR9 in colonic inflammatory bowel disease - reading between the lines
Trivedi, P. J.
Schmidt, C.
Bruns, T.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (03) : 307 - 308
[10] Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease
Walters, Matthew J.
Wang, Yu
Lai, Nu
Baumgart, Trageen
Zhao, Bin N.
Dairaghi, Daniel J.
Bekker, Pirow
Ertl, Linda S.
Penfold, Mark E. T.
Jaen, Juan C.
Keshav, Satish
Wendt, Emily
Pennell, Andrew
Ungashe, Solomon
Wei, Zheng
Wright, J. J. Kim
Schall, Thomas J.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (01): : 61 - 69

← 1 2 3 4 5 →